UNIQURE NV's ticker is QURE and the CUSIP is N90064101. A total of 133 filers reported holding UNIQURE NV in Q1 2019. The put-call ratio across all filers is 0.11 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $478,000 | -7.4% | 25,499 | -7.9% | 0.01% | 0.0% |
| Q2 2022 | $516,000 | -40.2% | 27,675 | -42.0% | 0.01% | -44.4% |
| Q1 2022 | $863,000 | -22.2% | 47,743 | -10.7% | 0.01% | -25.0% |
| Q4 2021 | $1,109,000 | -59.6% | 53,470 | -34.3% | 0.01% | -55.6% |
| Q1 2021 | $2,742,000 | -5.5% | 81,401 | +1.3% | 0.03% | -18.2% |
| Q4 2020 | $2,903,000 | +39.0% | 80,337 | +41.7% | 0.03% | +6.5% |
| Q3 2020 | $2,088,000 | -20.5% | 56,680 | -2.8% | 0.03% | -11.4% |
| Q2 2020 | $2,627,000 | -28.7% | 58,307 | -25.0% | 0.04% | -38.6% |
| Q1 2020 | $3,687,000 | -40.2% | 77,712 | -9.7% | 0.06% | +18.8% |
| Q4 2019 | $6,168,000 | +84.0% | 86,067 | +1.0% | 0.05% | +84.6% |
| Q3 2019 | $3,353,000 | -45.3% | 85,178 | +8.5% | 0.03% | -42.2% |
| Q2 2019 | $6,133,000 | +15.2% | 78,475 | -12.0% | 0.04% | +18.4% |
| Q1 2019 | $5,322,000 | +116.3% | 89,224 | +4.5% | 0.04% | +100.0% |
| Q4 2018 | $2,460,000 | – | 85,364 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 155,500 | $11,803,000 | 2.66% |
| Aquilo Capital Management, LLC | 901,490 | $16,290,000 | 2.39% |
| Nantahala Capital Management | 2,811,459 | $50,803,000 | 2.25% |
| Privium Fund Management B.V. | 493,229 | $8,913,000 | 1.97% |
| 683 Capital Management, LLC | 1,355,000 | $24,485,000 | 1.31% |
| Henry James International Management Inc. | 125,622 | $2,270,000 | 0.90% |
| Integral Health Asset Management, LLC | 170,000 | $3,072,000 | 0.80% |
| Nantahala Capital Management | 890,000 | $16,082,000 | 0.71% |
| Sonic Fund II, L.P. | 50,000 | $904,000 | 0.51% |
| Voss Capital, LLC | 70,000 | $1,265,000 | 0.40% |